Natco Pharma’s arm completes acquisition of Dash Pharmaceuticals

03 Jan 2022 Evaluate

Natco Pharma’s wholly owned subsidiary -- NATCO Pharma Inc. USA, has completed the acquisition of Dash Pharmaceuticals (Dash), a New Jersey based entity. Pursuant to this, Dash will become a 100% wholly owned subsidiary of NATCO Pharma Inc. and a step-down subsidiary of NATCO. The acquisition amount paid is $18 million.

Dash is a front-end pharmaceutical sales, marketing and distribution entity in the USA which is expected to have Net Sales of approximately $15 million for the financial year ending December 2021.

This acquisition provides NATCO with a platform to engage with its customers directly in the USA which is the largest pharmaceutical market in the world.

Natco Pharma was promoted as a private company to be in the business of research, developing, manufacturing and marketing of pharmaceutical substances and finished dosage forms for Indian and International markets.

Natco Pharma Share Price

899.95 2.90 (0.32%)
31-Dec-2025 09:47 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1720.95
Dr. Reddys Lab 1260.70
Cipla 1490.65
Zydus Lifesciences 906.35
Lupin 2086.10
View more..
Register Now to get our Free Newsletter & much more!

© 2025 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×